JP2020519308A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519308A5
JP2020519308A5 JP2020512919A JP2020512919A JP2020519308A5 JP 2020519308 A5 JP2020519308 A5 JP 2020519308A5 JP 2020512919 A JP2020512919 A JP 2020512919A JP 2020512919 A JP2020512919 A JP 2020512919A JP 2020519308 A5 JP2020519308 A5 JP 2020519308A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020512919A
Other languages
English (en)
Japanese (ja)
Other versions
JP7118135B2 (ja
JP2020519308A (ja
JPWO2018206790A5 (enExample
Filing date
Publication date
Priority claimed from GBGB1707561.5A external-priority patent/GB201707561D0/en
Application filed filed Critical
Publication of JP2020519308A publication Critical patent/JP2020519308A/ja
Publication of JP2020519308A5 publication Critical patent/JP2020519308A5/ja
Publication of JPWO2018206790A5 publication Critical patent/JPWO2018206790A5/ja
Priority to JP2022122483A priority Critical patent/JP2022169549A/ja
Application granted granted Critical
Publication of JP7118135B2 publication Critical patent/JP7118135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020512919A 2017-05-11 2018-05-11 GARP-TGF-β抗体 Active JP7118135B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022122483A JP2022169549A (ja) 2017-05-11 2022-08-01 GARP-TGF-β抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1707561.5 2017-05-11
GBGB1707561.5A GB201707561D0 (en) 2017-05-11 2017-05-11 GARP-TGF-beta antibodies
PCT/EP2018/062251 WO2018206790A1 (en) 2017-05-11 2018-05-11 GARP-TGF-β ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022122483A Division JP2022169549A (ja) 2017-05-11 2022-08-01 GARP-TGF-β抗体

Publications (4)

Publication Number Publication Date
JP2020519308A JP2020519308A (ja) 2020-07-02
JP2020519308A5 true JP2020519308A5 (enExample) 2021-06-10
JPWO2018206790A5 JPWO2018206790A5 (enExample) 2022-01-25
JP7118135B2 JP7118135B2 (ja) 2022-08-15

Family

ID=59201573

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512919A Active JP7118135B2 (ja) 2017-05-11 2018-05-11 GARP-TGF-β抗体
JP2022122483A Withdrawn JP2022169549A (ja) 2017-05-11 2022-08-01 GARP-TGF-β抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022122483A Withdrawn JP2022169549A (ja) 2017-05-11 2022-08-01 GARP-TGF-β抗体

Country Status (35)

Country Link
US (4) US10479829B2 (enExample)
EP (3) EP3606961B8 (enExample)
JP (2) JP7118135B2 (enExample)
KR (2) KR20240065192A (enExample)
CN (1) CN110945027B (enExample)
AU (2) AU2018265241B2 (enExample)
BR (1) BR112019023735A8 (enExample)
CA (1) CA3061841C (enExample)
CL (1) CL2019003211A1 (enExample)
CO (1) CO2019013669A2 (enExample)
CR (1) CR20190561A (enExample)
CY (1) CY1125674T1 (enExample)
DK (1) DK3606961T3 (enExample)
DO (1) DOP2019000285A (enExample)
EC (1) ECSP19087742A (enExample)
ES (1) ES2921015T3 (enExample)
GB (1) GB201707561D0 (enExample)
HR (1) HRP20220787T1 (enExample)
HU (1) HUE059237T2 (enExample)
IL (2) IL270236B2 (enExample)
LT (1) LT3606961T (enExample)
MX (1) MX385670B (enExample)
MY (1) MY199335A (enExample)
NZ (1) NZ758647A (enExample)
PE (1) PE20200618A1 (enExample)
PH (1) PH12019502526A1 (enExample)
PL (1) PL3606961T3 (enExample)
PT (1) PT3606961T (enExample)
RS (1) RS63361B1 (enExample)
RU (1) RU2767784C2 (enExample)
SG (1) SG10201914130VA (enExample)
SI (1) SI3606961T1 (enExample)
SM (1) SMT202200284T1 (enExample)
UA (1) UA125534C2 (enExample)
WO (1) WO2018206790A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3960855A1 (en) * 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
CN120025435A (zh) 2019-08-28 2025-05-23 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
CA3155172A1 (en) 2019-10-25 2021-04-29 Shinko HAYASHI Combination of anti-garp antibody and immunomodulator
AU2021205433A1 (en) * 2020-01-11 2022-08-18 Scholar Rock, Inc. Tgfß inhibitors and use thereof
CN115243724B (zh) 2020-02-19 2025-10-21 纳米医疗有限公司 可用于治疗癌症的经调配和/或共调配的含有TFGβ拮抗剂前药的脂质体组合物和其方法
US20230192867A1 (en) * 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
CA3201419A1 (en) * 2020-11-11 2022-05-19 Versapeutics Inc. Antibody variants against wnt receptor ryk
JP2023553861A (ja) 2020-12-02 2023-12-26 上海復宏漢霖生物技術股▲フン▼有限公司 抗GARP/TGFβ抗体及び使用方法
KR20230169936A (ko) * 2021-01-18 2023-12-18 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 Garp 단백질 항체 및 이의 적용
AR129351A1 (es) 2022-05-18 2024-08-14 Vestaron Corp Variantes de péptidos pesticidas actx
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル T細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのgarp
CN119630418A (zh) 2022-07-29 2025-03-14 艾伯维生物制药股份有限公司 抗GARP-TGF-β1/PD-1组合疗法
JP2026504831A (ja) 2023-01-09 2026-02-10 北京拓界生物医薬科技有限公司 TGFβ1結合分子、GARP-TGFβ1結合分子及びそれらの医薬的使用
WO2024164807A1 (zh) * 2023-02-06 2024-08-15 贝达药业股份有限公司 多特异性抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
NZ298145A (en) 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
WO2007113301A1 (en) 2006-04-03 2007-10-11 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
KR101492052B1 (ko) 2012-06-26 2015-02-10 (주)대창솔루션 액화가스 운반용 탱크
IN2015DN00140A (enExample) 2012-08-31 2015-06-12 Argen X Bv
SMT202100008T1 (it) 2013-05-06 2021-03-15 Scholar Rock Inc Composizioni e metodi per la modulazione di fattore di crescita
EA035550B1 (ru) 2013-08-01 2020-07-06 Юниверсите Католик Де Лувэн АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С КОМПЛЕКСОМ hGARP/TGF-B1, И ИХ ПРИМЕНЕНИЕ
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
PT3354729T (pt) * 2015-09-24 2024-04-11 Daiichi Sankyo Co Ltd Anticorpo anti-garp
AU2017294772B2 (en) * 2016-07-14 2024-05-02 Scholar Rock, Inc. TGFB antibodies, methods, and uses

Similar Documents

Publication Publication Date Title
JP2020519308A5 (enExample)
JP2017169559A5 (enExample)
JP2020504101A5 (enExample)
HRP20220787T1 (hr) Protutijela protiv garp-tgf-beta
JP2018526981A5 (enExample)
JP2020184996A5 (enExample)
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2009537608A5 (enExample)
JP2020508655A5 (enExample)
JP2019525738A5 (enExample)
RU2009128064A (ru) Антитела к cd44
JP2020525032A5 (enExample)
JP2013545455A5 (enExample)
HRP20201993T1 (hr) Protutijela protiv pd-1
JP2018183173A5 (enExample)
JP2023134618A5 (enExample)
JP2012501670A5 (enExample)
RU2008129111A (ru) Антитела к ox40l и способы их применения
JP2009523459A5 (enExample)
JP2016512551A5 (enExample)
FI3310812T3 (fi) Anti-her2-vasta-aineita ja käyttömenetelmiä
RU2011116927A (ru) Антитела против интерлейкина 17 (ил-17) человека и их применение
JP2014534242A5 (enExample)
JP2010532764A5 (enExample)
JPWO2019129221A5 (enExample)